NCT07219550View on ClinicalTrials.gov

A Study of MK-1084 in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

April 17, 2026

Study Completion Date

April 17, 2026

Conditions

HealthyHepatic Impairment

Interventions

DRUG

MK-1084

Oral Tablet

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY